Blood filtering shows promise for high lipoprotein(a) in dialysis patients

NCT ID NCT07390604

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small completed study looked at a blood filtering procedure called double-filtration plasmapheresis (DFPP) in 5 kidney dialysis patients with very high levels of lipoprotein(a), a fatty substance linked to heart disease and blood clots. The goal was to see if DFPP could lower those levels and possibly reduce cardiovascular risk. The study measured Lp(a) before and after each session, but because it was a tiny case series without a comparison group, the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Double-filtration plasmapheresis (DFPP)
What this could lead to
If this works, it could point toward a way to lower heart and clot risks in kidney dialysis patients with very high lipoprotein(a).
What could go wrong
This is a tiny case series (5 people) with no control group, so results may not apply to others. The procedure is invasive and not a long-term fix.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHR Metz-Thionville Hopital de Mercy

    Metz, 57085, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.